We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Robotic Next Generation Sequencing Platform Accurately Screens Thousands of COVID-19 Samples at Once

By LabMedica International staff writers
Posted on 04 Mar 2021
Print article
Image: Jeff Wrana, left, is seen in this undated file photo at the Lunenfeld-Tanenbaum Research Institute in Toronto, Canada (Photo courtesy of Sinai Health)
Image: Jeff Wrana, left, is seen in this undated file photo at the Lunenfeld-Tanenbaum Research Institute in Toronto, Canada (Photo courtesy of Sinai Health)
A robotics platform to screen thousands of COVID-19 samples at once has the potential to revolutionize how labs track the spread of viruses and other pathogens, according to new findings.

The study by researchers from the Lunenfeld-Tanenbaum Research Institute (LTRI) at Sinai Health (Toronto, ON, Canada) found that their next-generation, ultra-high-throughput sequencing platform, called C19-SPAR-Se, has a sensitivity rate greater than 95% in positive cases during peak onset. The platform is also cost-effective. The study notes it only costs about USD 8 per test when running thousands of samples at once, as the cost per sample decreases due to economies of scale.

"Identifying positive samples quickly and accurately is critical in beating this pandemic," said Dr. Jeff Wrana, senior investigator at the LTRI and professor in the Department of Molecular Genetics at the University of Toronto. "With new and potentially dangerous variants now circulating, this is a platform that is scalable, automated and capable of analyzing thousands of COVID-19 patient samples in a single instrument run."

Related Links:
Lunenfeld-Tanenbaum Research Institute

Gold Supplier
Sample Transport
VACUETTE Transport Line
New
SARS-CoV-2 Recombinant Antigens
SARS-CoV-2 Recombinant Antigens
Immunoassay Reader
ichroma II
New
Preterm Delivery Test (phIGFBP-1)
Actim Partus 1ngeni

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.